266 related articles for article (PubMed ID: 19135530)
1. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
[TBL] [Abstract][Full Text] [Related]
3. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats.
Neerati P; Ganji D; Bedada SK
Eur J Pharm Sci; 2011 Sep; 44(1-2):27-31. PubMed ID: 21640186
[TBL] [Abstract][Full Text] [Related]
4. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
Stewart CF; Zamboni WC; Crom WR; Houghton PJ
Cancer Chemother Pharmacol; 1997; 40(3):259-65. PubMed ID: 9219511
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Gupta E; Safa AR; Wang X; Ratain MJ
Cancer Res; 1996 Mar; 56(6):1309-14. PubMed ID: 8640819
[TBL] [Abstract][Full Text] [Related]
7. Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism.
Xing H; Luo X; Li Y; Fan C; Liu N; Cui C; Li W
Pharm Biol; 2020 Dec; 58(1):152-156. PubMed ID: 31990625
[No Abstract] [Full Text] [Related]
8. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
Lin LC; Wang MN; Tsai TH
Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
[TBL] [Abstract][Full Text] [Related]
9. Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
Ahmad N; Alam MA; Ahmad R; Umar S; Jalees Ahmad F
J Microencapsul; 2018 Jun; 35(4):327-343. PubMed ID: 29873288
[TBL] [Abstract][Full Text] [Related]
10. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.
Nakamura Y; Satake K; Sano K; Ito A; Yoshikawa M; Ikegami Y; Yoshida H; Nakano H; Oka M; Sawada S; Soda H; Kohno S
Chemotherapy; 2008; 54(6):485-91. PubMed ID: 18832822
[TBL] [Abstract][Full Text] [Related]
12. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
[TBL] [Abstract][Full Text] [Related]
13. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
14. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
15. Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats.
Choi DH; Chang KS; Hong SP; Choi JS; Han HK
Biopharm Drug Dispos; 2008 Jan; 29(1):45-50. PubMed ID: 17941000
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
[TBL] [Abstract][Full Text] [Related]
17. Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats.
Piao YJ; Li X; Choi JS
Eur J Drug Metab Pharmacokinet; 2008; 33(3):159-64. PubMed ID: 19007041
[TBL] [Abstract][Full Text] [Related]
18. Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation.
Negi LM; Tariq M; Talegaonkar S
Colloids Surf B Biointerfaces; 2013 Nov; 111():346-53. PubMed ID: 23850745
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
20. Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
de Jong FA; Kitzen JJ; de Bruijn P; Verweij J; Loos WJ
Cancer Biol Ther; 2006 Sep; 5(9):1105-10. PubMed ID: 16969123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]